Cytotoxicity of SGN-CD33A and GO in AML cell lines
| Cell line . | Cell type . | CD33 receptor copy number . | MDR status . | Flt3 mutation* . | NPM1 mutation* . | p53 status* . | IC50 (ng/mL) . | |
|---|---|---|---|---|---|---|---|---|
| SGN-CD33A . | GO . | |||||||
| KG-1 | AML | 23 000 | + | No | No | Mutant | 3 | 227 |
| HEL 92.1.7 | AML | 19 000 | + | No | No | Mutant | 7 | >1000 |
| TF1-α | AML | 17 000 | + | No | NT | Wild-type + Mutant | 49 | >1000 |
| TF-1 | AML | 6000 | + | No | NT | Wild-type + Mutant | 61 | >1000 |
| HNT-34 | AML | 22 000 | +/− | No | NT | NT | 26 | 33 |
| U937 | AML | 20 000 | +/− | No | NT | Mutant | 22 | 19 |
| MV4-11 | AML | 18 000 | +/− | Yes | No | Wild-type | 0.1 | 6 |
| Shi-1 | AML | 25 000 | — | NT | NT | Mutant | 6 | NT |
| THP-1 | AML | 18 000 | — | No | No | Deletion | 7 | 6 |
| HL-60 | AML | 17 000 | — | No | No | Deletion | 1 | 2 |
| SIG-M5 | AML | 13 000 | — | No | No | Wild-type | 7.5 | 7 |
| SH-2 | AML | 7000 | — | NT | NT | Mutant | 68 | 168 |
| Ramos | NHL | 0 | NT | No | No | Mutant | >1000 | NT |
| ES-2 | Ovarian Carcinoma | 0 | NT | Mutant | >1000 | 300 | ||
| SKOV-3 | Ovarian Carcinoma | 0 | NT | No | No | Deletion | >5000 | >5000 |
| Cell line . | Cell type . | CD33 receptor copy number . | MDR status . | Flt3 mutation* . | NPM1 mutation* . | p53 status* . | IC50 (ng/mL) . | |
|---|---|---|---|---|---|---|---|---|
| SGN-CD33A . | GO . | |||||||
| KG-1 | AML | 23 000 | + | No | No | Mutant | 3 | 227 |
| HEL 92.1.7 | AML | 19 000 | + | No | No | Mutant | 7 | >1000 |
| TF1-α | AML | 17 000 | + | No | NT | Wild-type + Mutant | 49 | >1000 |
| TF-1 | AML | 6000 | + | No | NT | Wild-type + Mutant | 61 | >1000 |
| HNT-34 | AML | 22 000 | +/− | No | NT | NT | 26 | 33 |
| U937 | AML | 20 000 | +/− | No | NT | Mutant | 22 | 19 |
| MV4-11 | AML | 18 000 | +/− | Yes | No | Wild-type | 0.1 | 6 |
| Shi-1 | AML | 25 000 | — | NT | NT | Mutant | 6 | NT |
| THP-1 | AML | 18 000 | — | No | No | Deletion | 7 | 6 |
| HL-60 | AML | 17 000 | — | No | No | Deletion | 1 | 2 |
| SIG-M5 | AML | 13 000 | — | No | No | Wild-type | 7.5 | 7 |
| SH-2 | AML | 7000 | — | NT | NT | Mutant | 68 | 168 |
| Ramos | NHL | 0 | NT | No | No | Mutant | >1000 | NT |
| ES-2 | Ovarian Carcinoma | 0 | NT | Mutant | >1000 | 300 | ||
| SKOV-3 | Ovarian Carcinoma | 0 | NT | No | No | Deletion | >5000 | >5000 |
CD33+ AML cells and CD33-negative cell lines were incubated with increasing concentrations of SGN-CD33A or GO for 96 hours before processing with CelltiterGlo. Data are expressed as IC50, the concentration of ADC required to give a 50% reduction in cell viability. CD33 receptor copy number (copies/cell) was determined by flow cytometry, using the DAKO QiFi kit. MDR, multidrug resistance; NT, not tested; +, rhodamine dye efflux more than 2-fold above background.
http://www.sanger.ac.uk/genetics/CGP/cell lines/ and Drexler HG. DSMZ guide to Leukemic-Lymphoma Cell Lines (http://www.dsmz.de/research/human-and-animal-cell-lines/guide-to-leukemia-lymphoma-cell-lines.html).